- TRADE NAME: Oxlumo (Alnylam Pharma Inc)
- INDICATIONS: Treatment of primary hyperoxaluria type 1. To lower urinary oxalate levels in pediatric and adult patients.
- CLASS: Small interfering RNA (siRNA)
- HALF-LIFE: approximately 5 hours
- FDA APPROVAL DATE: 11/23/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: No available data in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
